Search

Crinetics Pharmaceuticals Inc

Suletud

SektorTervishoid

83.91 0.06

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

83.82

Max

83.89

Põhinäitajad

By Trading Economics

Sissetulek

-5M

-128M

Müük

6.8M

11M

Aktsiakasum

-1.23

Kasumimarginaal

-1,191.029

Töötajad

594

EBITDA

-5M

-127M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

-1.96% downside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

4. aug 2026

Turustatistika

By TradingEconomics

Turukapital

4.5B

8.9B

Eelmine avamishind

83.85

Eelmine sulgemishind

83.91

Uudiste sentiment

By Acuity

22%

78%

44 / 340 Pingereas Healthcare

Crinetics Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. juuli 2026, 23:56 UTC

News

Brookdale Senior Living announced its second-quarter 2026 earnings release dates, boosting investor sentiment. Shares are trading higher in after-market hours.

20. juuli 2026, 23:56 UTC

News

Valero Energy Corp gains in after-market trading on strong earnings forecast, with projected EPS of $9.81 and revenue expectations of $35.95 billion.

20. juuli 2026, 23:51 UTC

News
Correlated Moves

Ally Financial shares are lower in after-market trading despite the board declaring a quarterly cash dividend of $0.30 per share.

20. juuli 2026, 23:51 UTC

Social Media
News

Magnolia Oil & Gas announced a $1 billion stock offering to fund the acquisition of WildFire Intermediate Holdings, resulting in a sharp decline in after-market hours.

20. juuli 2026, 23:46 UTC

News

Advanced Energy Industries gained after-market hours following $31 million in funding for the Idaho Advanced Energy Consortium's Nuclear Energy Corridor Tech Hub initiative.

20. juuli 2026, 23:46 UTC

News

Ross Stores announced 47 new locations but shares are trading lower in after-market hours following Monday's close. The company plans to open about 110 stores in 2026.

20. juuli 2026, 23:46 UTC

News

Monarch Casino & Resort Inc reports record Q2 revenue of $142.6 million and EPS of $1.78, trading higher in after-market hours.

20. juuli 2026, 23:46 UTC

News

Sweetgreen Inc shares are higher in after-market trading, despite ongoing concerns in the restaurant sector over a cyclospora outbreak linked to iceberg lettuce.

20. juuli 2026, 23:46 UTC

News

Warner Bros Discovery shares are lower in after-market hours as a judge pauses the $110 billion Paramount Skydance acquisition, extending legal uncertainty.

20. juuli 2026, 23:41 UTC

News
Event

Calix Inc's stock is lower in after-market trading following a mixed earnings report and a disappointing third-quarter outlook, alongside a class action lawsuit.

20. juuli 2026, 23:36 UTC

News

GameStop shares are lower in after-market hours as the company proposes a stock-based acquisition of eBay, introducing significant new debt and operational changes.

20. juuli 2026, 23:36 UTC

News
Correlated Moves

Invesco Ltd's shares rose during after-market hours, reflecting a modest increase since Monday's close, alongside gains in the Invesco S&P 500 High Dividend Low Volatility ETF.

20. juuli 2026, 23:36 UTC

News

Jazz Pharmaceuticals PLC will report second-quarter results on August 3, contributing to positive investor sentiment as shares trade higher after market hours.

20. juuli 2026, 23:32 UTC

News

Broadcom Inc. shares are higher in after-hours trading, driven by strong historical returns and potential growth from Meta Platforms' AI chip production plans.

20. juuli 2026, 23:26 UTC

News
Correlated Moves

Blackstone Inc. shares are higher in after-market trading following a $676 million investment in South Korea's Futronic, enhancing its technology portfolio.

20. juuli 2026, 23:16 UTC

News

Enphase Energy shares fell after TD Cowen cut its price target from $70 to $48, citing a challenging solar market and weaker demand. The stock was roughly flat in after-market trading.

20. juuli 2026, 23:16 UTC

News
Social Media

Alphabet Inc shares are higher in after-market hours as reports reveal plans for a new AI chip that may significantly outperform current models.

20. juuli 2026, 23:16 UTC

News

Quanta Services reported a $48 billion backlog, signaling strong revenue potential. Shares moved higher in after-market hours amid bullish analyst sentiment.

20. juuli 2026, 23:06 UTC

News

ServiceNow Inc. shares are trading lower in after-market hours amid bearish sentiment over potential disruptions from generative AI and rising Treasury yields.

20. juuli 2026, 23:06 UTC

News

Pomerantz LLP has filed a class action lawsuit against Lucid Group Inc, alleging securities fraud related to misleading statements about operational capabilities and performance.

20. juuli 2026, 23:06 UTC

News
Social Media

General Electric Co advances in aviation technology with a hybrid-electric flight demonstration and secures an engine deal with Philippine Airlines, shares higher after-market.

20. juuli 2026, 23:06 UTC

News

Geopolitical tensions, particularly between the U.S. and Iran, have impacted global consumer sentiment. Nike shares were little changed during after-market hours.

20. juuli 2026, 23:06 UTC

News

Yum Brands Inc shares declined after a report of reduced foot traffic at Taco Bell due to a parasite outbreak linked to lettuce supplied by a vendor.

20. juuli 2026, 23:02 UTC

News

Zions Bancorporation NA reported Q2 earnings of $452 million, or $3.05 per share, but shares are lower in after-market trading amid mixed results.

20. juuli 2026, 23:02 UTC

News

W. R. Berkley Corporation reported strong second-quarter earnings but missed revenue expectations. Shares declined during after-market hours amid notable volatility.

20. juuli 2026, 23:01 UTC

News

Coca-Cola Consolidated Inc shares rose during after-market hours, reflecting positive sentiment in the beverage sector despite earlier session volatility.

20. juuli 2026, 23:01 UTC

News

Karyopharm Therapeutics shares fell in after-market hours following the announcement of a leadership cash retention program aimed at key executives.

20. juuli 2026, 23:01 UTC

Social Media
News

Park Aerospace Corp reported first-quarter earnings of $0.17 per share, exceeding estimates, and is trading higher in after-market hours.

20. juuli 2026, 23:01 UTC

News
Event

Cracker Barrel completed a sale-leaseback for 26 locations, generating $77 million. Shares are trading higher after exceeding previous revenue guidance.

20. juuli 2026, 23:01 UTC

News
Social Media
Event

Crown Holdings reported second-quarter adjusted EPS of $2.49, exceeding estimates. The company raised its full-year EPS guidance, with shares higher in after-market hours.

Võrdlus sarnastega

Hinnamuutus

Crinetics Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

-1.96% langus

12 kuu keskmine prognoos

Keskmine 82.22 USD  -1.96%

Kõrge 95 USD

Madal 55 USD

Põhineb 14 Wall Streeti analüütiku instrumendi Crinetics Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

14 ratings

3

Osta

11

Hoia

0

Müü

Sentiment

By Acuity

44 / 340 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
help-icon Live chat